1. A 66-year-old woman with hypertension, type 2 diabetes, and HFrEF (EF 38%) is currently on sacubitril/valsartan, spironolactone, and furosemide. Her BP is 154/88 mmHg. Her cardiologist wants to add a beta-blocker for guideline-directed therapy. Which of the following correctly identifies the appropriate agent and starting strategy?
A) Add propranolol 80 mg twice daily — non-selective beta-blockade provides the broadest sympathetic suppression in HFrEF and is preferred over cardioselective agents when ejection fraction is severely reduced
B) Add atenolol 50 mg daily — its renal elimination makes it preferable in HFrEF because hepatic metabolism of other beta-blockers is impaired by reduced hepatic blood flow in low-output states
C) Add carvedilol 3.125 mg twice daily or metoprolol succinate 12.5–25 mg daily — both are guideline-directed evidence-based beta-blockers for HFrEF; initiate at the lowest available dose in stable, euvolemic patients and titrate slowly over weeks to months; avoid initiation during acute decompensation; the goal is the maximum tolerated dose
D) Add bisoprolol 10 mg daily starting dose — higher initial doses are better tolerated in HFrEF because they achieve receptor saturation more rapidly, reducing the reflex tachycardia that occurs during slow titration
E) Add labetalol 100 mg twice daily — its combined alpha and beta blockade provides simultaneous blood pressure reduction and HFrEF mortality benefit, making it the most efficient single agent for this patient's combined indications
ANSWER: C
Rationale:
Three beta-blockers have demonstrated mortality benefit in HFrEF in landmark randomized controlled trials and are the only evidence-based options: carvedilol (US Carvedilol Heart Failure Study, COPERNICUS), metoprolol succinate (MERIT-HF), and bisoprolol (CIBIS-II). The cardinal rule of beta-blocker initiation in HFrEF is to start at the lowest available dose in a stable, euvolemic patient and titrate upward slowly — typically doubling the dose no more frequently than every 2 weeks — toward the target dose used in the landmark trials. Beta-blockers must never be started during acute decompensation. The rationale for slow titration is that the HFrEF myocardium is dependent on elevated sympathetic tone to maintain output; abrupt or high-dose beta-blockade can precipitate acute hemodynamic decompensation.
Option A: Option A is incorrect because propranolol is non-selective and does not have outcome trial evidence for HFrEF mortality reduction; it is not one of the three guideline-directed beta-blockers.
Option B: Option B is incorrect because atenolol also lacks HFrEF outcome trial evidence; the choice between hepatic and renally eliminated agents is not the relevant pharmacological rationale for HFrEF agent selection.
Option D: Option D is incorrect because beta-blockers in HFrEF must be initiated at the lowest dose, not the target dose; high initial doses risk acute decompensation.
Option E: Option E is incorrect because labetalol does not have HFrEF outcome trial evidence for mortality reduction; while carvedilol (also a combined alpha/beta blocker) does, labetalol is not substitutable for carvedilol on the basis of shared receptor pharmacology alone.
2. A 58-year-old man with hypertension, stable angina, and no heart failure is on amlodipine 10 mg daily. His BP is 148/86 mmHg and he continues to have exertional angina two to three times per week despite the CCB. His physician considers adding a second agent. Which of the following correctly explains why a beta-blocker is pharmacologically preferred as the second agent in this specific clinical context?
A) A beta-blocker should be added because it will provide additional blood pressure lowering through renin suppression, which amlodipine does not address, creating a complementary RAAS-independent plus RAAS-dependent mechanism
B) A beta-blocker is preferred because amlodipine causes reflex tachycardia in some patients, and the beta-blocker will reduce the heart rate to offset the tachycardia and provide additive antihypertensive benefit
C) A beta-blocker is contraindicated in combination with amlodipine because both agents reduce cardiac output through different mechanisms, producing additive hemodynamic compromise
D) A beta-blocker is preferred as second agent because it will convert stable angina to unstable angina by reducing coronary vasospasm, which amlodipine was suppressing through calcium channel blockade
E) A beta-blocker is pharmacologically ideal as the second agent in stable angina — it reduces myocardial oxygen demand by slowing heart rate and reducing contractility, directly targeting the demand side of the supply-demand mismatch that causes anginal symptoms; the combination of amlodipine (coronary and peripheral vasodilation, increasing supply) and a beta-blocker (rate and contractility reduction, decreasing demand) addresses both sides of the ischemia equation simultaneously; this combination is a guideline-recommended approach for refractory stable angina
ANSWER: E
Rationale:
Stable angina results from a supply-demand mismatch — coronary blood flow is insufficient to meet myocardial oxygen demand during exertion. Amlodipine addresses the supply side: it dilates coronary arteries (reducing coronary vasospasm and improving flow) and reduces peripheral arteriolar resistance (reducing afterload and wall stress). A beta-blocker addresses the demand side: beta-1 blockade at the sinoatrial node reduces heart rate (extending diastole, which is when coronary perfusion occurs), and reduces myocardial contractility — both major determinants of myocardial oxygen consumption. The combination of amlodipine plus a beta-blocker is well-established and guideline-supported for stable angina with inadequate symptom control on a single agent, addressing both sides of the ischemia equation through complementary and non-redundant mechanisms. Additionally, amlodipine can cause mild reflex tachycardia (through baroreceptor-mediated sympathetic activation from its vasodilatory effect), and the beta-blocker can attenuate this. The combination is also safe — DHP CCBs do not suppress AV nodal conduction and therefore do not compound the beta-blocker's cardiac conduction effects. Option B is partially correct (reflex tachycardia attenuation) but is incomplete — the primary antianginal rationale is demand reduction, not solely counteracting CCB-induced tachycardia.
Option A: Option A is incorrect because the pharmacological rationale in stable angina is anti-ischemic, not RAAS-based; renin suppression is a secondary effect of beta-blockers, not the primary indication here.
Option C: Option C is incorrect because beta-blockers and amlodipine do not both reduce cardiac output; amlodipine reduces peripheral resistance without directly depressing myocardial contractility.
Option D: Option D is incorrect because beta-blockers do not convert stable to unstable angina; they are used to treat both stable and vasospastic angina (with some caveats for vasospastic angina regarding non-selective agents).
3. A 72-year-old man with hypertension and known Raynaud phenomenon develops worsening of his Raynaud symptoms after his primary care physician starts metoprolol succinate 25 mg daily for rate control in newly diagnosed atrial fibrillation. His fingertips are now turning white and blue in even mild cold exposure. Which of the following best explains the pharmacological mechanism and the most appropriate management?
A) Metoprolol succinate, despite being cardioselective, retains some beta-2 receptor blocking activity — in Raynaud phenomenon, where digital vessels are abnormally reactive to sympathetic stimulation, even partial beta-2 blockade in digital vascular smooth muscle can tip the balance toward unopposed alpha-1-mediated vasospasm; the appropriate management is to switch to a non-beta-blocker rate control agent — diltiazem is pharmacologically ideal as it provides AV nodal rate control for AF without beta-2 blockade, and non-DHP CCBs also have vasodilatory properties in digital vessels that may actually improve Raynaud symptoms
B) Metoprolol worsens Raynaud phenomenon through its anti-renin effect — reduced renin lowers angiotensin II, removing angiotensin II-mediated vasodilation in digital vessels; switching to an ARB will restore digital vasodilation
C) Metoprolol worsens Raynaud through direct alpha-1 agonist activity that it develops at high plasma concentrations; dose reduction to 12.5 mg will eliminate this effect while maintaining rate control
D) Metoprolol worsens Raynaud because beta-1 blockade in the heart reduces cardiac output, decreasing digital perfusion pressure to below the threshold needed to maintain digital flow against the elevated sympathetic vasoconstriction in Raynaud; a loop diuretic should be added to reduce preload and paradoxically improve digital perfusion
E) Cardioselective beta-blockers have no effect on Raynaud phenomenon; the worsening symptoms are coincidental and unrelated to metoprolol; no medication change is needed
ANSWER: A
Rationale:
Raynaud phenomenon involves exaggerated digital vasoconstriction in response to cold or emotional stress, mediated through abnormal alpha-1 adrenoceptor reactivity in digital vessels. In normal physiology, digital vascular tone reflects a balance between alpha-1-mediated vasoconstriction and beta-2-mediated vasodilation. Although metoprolol succinate is cardioselective (preferentially blocking beta-1 receptors), its selectivity is relative and dose-dependent — at clinical doses, some beta-2 receptor blockade occurs in peripheral vascular smooth muscle. In patients with Raynaud phenomenon, whose digital vessels are already prone to vasospasm, this partial beta-2 blockade removes the beta-2-mediated vasodilatory counterbalance, leaving alpha-1-mediated vasoconstriction more unopposed and worsening cold-induced vasospasm. Switching to diltiazem for AF rate control is pharmacologically ideal — it provides AV nodal rate control through calcium channel blockade without any beta-2 receptor effects, and non-DHP CCBs have vasodilatory properties in peripheral vessels that may actually improve, rather than worsen, Raynaud symptoms.
Option B: Option B is incorrect because the mechanism of Raynaud worsening is beta-2 blockade in digital vessels, not anti-renin effect; angiotensin II is not a vasodilator in digital vessels.
Option C: Option C is incorrect because metoprolol does not develop alpha-1 agonist activity at any dose; this mechanism does not exist.
Option D: Option D is incorrect because the primary mechanism is peripheral vascular, not hemodynamic from reduced cardiac output; adding a diuretic would not improve digital vasospasm.
Option E: Option E is incorrect because cardioselective beta-blockers do worsen Raynaud phenomenon — cardioselectivity is relative and does not eliminate peripheral beta-2 blockade; clinical data confirm this association.
4. A 61-year-old woman with treatment-resistant hypertension on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily has BP 166/98 mmHg. Her plasma renin activity is 0.3 ng/mL/hr (low) and potassium is 3.8 mEq/L. Her physician is considering a fourth agent. A colleague suggests doxazosin 4 mg daily. Another suggests spironolactone 25 mg daily. Which of the following best explains why spironolactone is pharmacologically superior in this patient?
A) Spironolactone is preferred because doxazosin causes hyperkalemia when combined with an ACE inhibitor, whereas spironolactone lowers potassium
B) Spironolactone is preferred because doxazosin was shown in PATHWAY-2 to be inferior to placebo in resistant hypertension, while spironolactone was superior to both doxazosin and bisoprolol
C) Doxazosin is preferred in this patient because her low PRA indicates high RAAS activity that alpha-1 blockade specifically counteracts, while spironolactone would worsen the RAAS activation
D) Spironolactone is pharmacologically superior in this patient because her low plasma renin activity indicates volume-dependent, aldosterone-mediated hypertension — the physiological state where MRA therapy is most effective, as demonstrated in PATHWAY-2; her potassium of 3.8 mEq/L is low-normal and spironolactone will tend to normalize it; doxazosin was shown in PATHWAY-2 to be significantly less effective than spironolactone as fourth-line therapy in resistant hypertension, and the ALLHAT trial showed doxazosin associated with higher cardiovascular event rates than chlorthalidone
E) Doxazosin and spironolactone are equally effective as fourth-line agents in resistant hypertension; the choice between them should be based solely on adverse effect profile, with doxazosin preferred in women to avoid spironolactone's sex hormone adverse effects
ANSWER: D
Rationale:
This patient has low plasma renin activity — a marker of volume-dependent, aldosterone-mediated physiology that predicts robust response to mineralocorticoid receptor antagonism. PATHWAY-2 (Prevention And Treatment of Hypertension With Algorithm-based therapy) was a randomized crossover trial specifically designed to identify the best fourth-line agent in resistant hypertension. Spironolactone produced the greatest blood pressure reduction (~8.7 mmHg systolic greater than placebo) and was superior to both bisoprolol and doxazosin. Critically, the response to spironolactone was greatest in patients with the lowest plasma renin activity — exactly this patient's profile — consistent with the hypothesis that low-renin resistant hypertension is driven by subclinical aldosterone excess amenable to MRA blockade. Her potassium of 3.8 mEq/L (low-normal, likely chlorthalidone-driven) means spironolactone is both appropriate and likely to raise potassium toward normal. The ALLHAT data further supports avoiding doxazosin as a cornerstone antihypertensive. Option B contains a factual error — doxazosin in PATHWAY-2 was inferior to spironolactone but was not inferior to placebo; it provided significant BP reduction compared to placebo.
Option A: Option A is incorrect because doxazosin does not cause hyperkalemia and spironolactone raises potassium (not lowers it).
Option C: Option C is incorrect because low PRA indicates renin suppression from volume expansion (not high RAAS activity), and this is precisely the physiology that predicts MRA response.
Option E: Option E is incorrect because PATHWAY-2 clearly demonstrated spironolactone's superiority over doxazosin; they are not equally effective as fourth-line agents.
5. A 49-year-old woman with hypertension is started on doxazosin 1 mg at bedtime. She calls the office the next morning reporting that she felt severely dizzy and nearly fainted when getting up to use the bathroom at 3 AM. Her BP at the time was measured by her husband at 82/54 mmHg. Which of the following most accurately explains why the bedtime dosing strategy was correct in principle but why the event still occurred, and what should be done next?
A) The event confirms that doxazosin is contraindicated in this patient — severe first-dose orthostatic hypotension is an indication to permanently discontinue the drug and switch to a different antihypertensive class
B) This is first-dose orthostatic hypotension — the most characteristic adverse effect of alpha-1 blockers, occurring when alpha-1-mediated venoconstriction is suddenly abolished, allowing venous pooling on standing and a drop in venous return; dosing at bedtime was correct because it minimizes the risk period to nighttime sleep when the patient is recumbent; however, nighttime bathroom visits remain a risk window; management is to continue doxazosin at 1 mg at bedtime with counseling on slow position changes, sitting on the edge of the bed before standing, and ensuring adequate hydration; subsequent dose increases should be made gradually
C) The event occurred because 1 mg is too low a dose — paradoxically, higher doses of doxazosin cause less orthostatic hypotension because receptor saturation produces a ceiling effect on the vasodilatory response; the dose should be increased to 4 mg immediately
D) The bedtime dosing strategy was incorrect — doxazosin should always be taken in the morning to ensure peak drug effects occur when the patient is active and upright, allowing baroreceptor adaptation to occur during waking hours
E) This event confirms that the patient has subclinical autonomic neuropathy that was unmasked by the first dose of doxazosin; a full autonomic function evaluation should be completed before any further antihypertensive therapy is initiated
ANSWER: B
Rationale:
First-dose orthostatic hypotension is the most characteristic and predictable adverse effect of alpha-1 blockers. When alpha-1 receptors in venous and arteriolar smooth muscle are suddenly blocked, the sympathetic vasoconstriction that maintains blood pressure on standing is abolished. Gravity causes venous pooling in dependent limbs, reducing venous return, cardiac output, and blood pressure — producing dizziness, lightheadedness, or syncope on standing. The bedtime dosing strategy was pharmacologically correct in principle: peak plasma levels occur approximately 2–3 hours after the dose, and by having the patient recumbent during this peak period, the risk of symptomatic orthostasis is reduced. However, nighttime bathroom visits represent a risk window — the patient must stand from a supine position during the period of peak alpha-1 blockade. Management is not discontinuation but counseling: sit on the edge of the bed for 30–60 seconds before standing, move slowly, maintain adequate hydration, and use nighttime lighting to navigate safely. Subsequent dose increases should be gradual (typically doubling at 2-week intervals) to allow baroreceptor adaptation.
Option A: Option A is incorrect because first-dose orthostatic hypotension is expected and manageable; it is not an indication for permanent discontinuation.
Option C: Option C is incorrect because the orthostatic hypotension effect of doxazosin is dose-dependent — higher doses produce more alpha-1 blockade and greater orthostatic risk, not less.
Option D: Option D is incorrect because morning dosing would place peak drug effect during active waking hours when the patient is frequently changing positions, worsening the orthostatic risk; bedtime dosing is the standard recommendation.
Option E: Option E is incorrect because first-dose orthostatic hypotension from an alpha-1 blocker in a pharmacologically naive patient does not diagnose underlying autonomic neuropathy; it is an expected drug effect.
6. A 38-year-old woman with hypertension and no other medical history asks her physician about starting antihypertensive therapy. She is 10 weeks pregnant. Her BP is 152/96 mmHg. Which of the following correctly identifies the antihypertensive agents that are appropriate in this setting and those that must be avoided?
A) Enalapril 10 mg daily is the preferred first-line agent in pregnant women with hypertension because its renoprotective effects prevent the kidney injury associated with gestational hypertension
B) Amlodipine 5 mg daily is absolutely contraindicated in pregnancy because calcium channel blockers inhibit uterine smooth muscle contractions necessary for fetal positioning and placental blood flow
C) Labetalol, methyldopa, and nifedipine extended-release are the three guideline-endorsed first-line oral antihypertensive agents in pregnancy; ACE inhibitors, ARBs, and direct renin inhibitors are absolutely contraindicated due to fetal renotoxicity causing oligohydramnios, renal tubular dysgenesis, and neonatal renal failure; spironolactone is avoided due to anti-androgenic effects on fetal sexual development; thiazide diuretics are generally avoided due to volume contraction and reduced uteroplacental perfusion
D) All antihypertensive drugs are contraindicated in the first trimester; pharmacological treatment should be deferred until the second trimester regardless of blood pressure severity
E) Hydrochlorothiazide is preferred in pregnancy because its natriuretic effect reduces the pathological volume expansion that drives gestational hypertension without any effect on fetal renal development
ANSWER: C
Rationale:
Antihypertensive drug selection in pregnancy requires balancing maternal blood pressure control against fetal safety. The three guideline-endorsed first-line oral agents — labetalol, methyldopa, and nifedipine extended-release — have the most robust safety data in pregnancy. Labetalol provides reliable BP control through combined alpha and beta blockade; IV labetalol is also used for acute severe hypertension in pregnancy. Methyldopa (converted to alpha-methylnorepinephrine, a central alpha-2 agonist) has the longest safety record of any antihypertensive in pregnancy with no adverse fetal neurodevelopmental outcomes over decades of follow-up. Nifedipine ER (a DHP CCB) is well tolerated and effective. The absolute contraindications are the RAAS inhibitors — ACEi, ARBs, and direct renin inhibitors — all interfere with fetal RAAS-dependent renal development, causing fetal renal tubular dysgenesis, oligohydramnios (from fetal anuria), limb contractures from oligohydramnios, neonatal renal failure, and calvarial hypoplasia. Spironolactone is avoided because its anti-androgenic metabolites can impair normal fetal sexual differentiation. Thiazide diuretics are generally avoided because volume contraction can reduce uteroplacental perfusion.
Option A: Option A is incorrect because ACEi are absolutely contraindicated in pregnancy due to fetal renotoxicity.
Option B: Option B is incorrect because nifedipine ER (a CCB) is one of the three first-line agents; CCBs at therapeutic doses do not clinically impair uteroplacental perfusion or fetal positioning.
Option D: Option D is incorrect because severe hypertension in pregnancy requires immediate pharmacological treatment regardless of trimester; deferral risks maternal stroke, eclampsia, and placental abruption.
Option E: Option E is incorrect because thiazide diuretics are avoided in pregnancy due to the risk of volume contraction reducing uteroplacental perfusion.
7. A 55-year-old man with hypertension is taking metoprolol succinate 100 mg daily and is well controlled at BP 128/76 mmHg. He is scheduled for elective hip replacement. The anesthesiologist instructs him to continue his metoprolol on the morning of surgery. The patient asks his internist whether this is correct. Which of the following best explains the pharmacological rationale for continuing perioperative beta-blockade?
A) Perioperative beta-blockers must always be stopped 48 hours before surgery because their negative inotropy prevents the compensatory cardiac output increase needed during the surgical stress response
B) Metoprolol should be stopped the night before surgery and restarted 48 hours postoperatively to allow the adrenergic stress response to protect against intraoperative hypotension
C) Perioperative continuation of metoprolol is correct only if the patient has known coronary artery disease; in patients without CAD, beta-blockers should be stopped before elective surgery to optimize the physiological response to anesthesia
D) Metoprolol should be replaced with IV esmolol intraoperatively because oral agents cannot be reliably absorbed under general anesthesia and unpredictable plasma levels risk breakthrough hypertension
E) Continuing metoprolol perioperatively in a patient already established on it is appropriate — abrupt beta-blocker discontinuation risks rebound tachycardia and hypertension from upregulated beta receptors, which can precipitate myocardial ischemia in the perioperative setting; established patients on chronic beta-blocker therapy should continue their medication through the perioperative period; this is distinct from the POISE trial findings which cautioned against initiating new beta-blockers immediately before surgery in beta-blocker-naive patients
ANSWER: E
Rationale:
The perioperative management of beta-blockers requires distinguishing between two distinct clinical situations. For patients already established on chronic beta-blocker therapy (like this patient on metoprolol succinate), continuation through the perioperative period is recommended by ACC/AHA guidelines. Abrupt discontinuation risks beta-adrenoceptor upregulation — during chronic beta-blockade, the receptor density increases as a compensatory response; sudden withdrawal removes the blockade from these upregulated receptors, causing rebound adrenergic activation with tachycardia, hypertension, and increased myocardial oxygen demand that can precipitate ischemia or MI in the perioperative setting. This rebound risk is the primary reason to continue established therapy. This is pharmacologically distinct from the POISE trial scenario, which evaluated initiating high-dose metoprolol succinate de novo immediately before surgery in beta-blocker-naive patients — a practice associated with increased stroke and mortality, possibly from hypotension and bradycardia in patients whose adrenoceptors were not adapted to beta-blockade.
Option A: Option A is incorrect because perioperative continuation of established beta-blockers is guideline-recommended; stopping them risks rebound.
Option B: Option B is incorrect because stopping and restarting creates the precise rebound risk that continuation is designed to prevent.
Option C: Option C is incorrect because the recommendation to continue established beta-blocker therapy perioperatively applies regardless of CAD status.
Option D: Option D is incorrect because patients can typically take oral medications with a small sip of water on the morning of surgery; IV conversion is not routinely required for established oral therapy.
8. A 64-year-old man with hypertension, type 2 diabetes, and a 20-pack-year smoking history presents with BP 162/94 mmHg. He has mild peripheral arterial disease (ABI 0.82) and mild COPD (FEV1 68% predicted). His physician wants to add a beta-blocker because the patient had a non-ST-elevation MI three months ago. Which of the following most accurately identifies the correct agent and the pharmacological reasoning?
A) Metoprolol succinate 25 mg daily is appropriate — it has outcome trial evidence for post-MI mortality reduction; as a cardioselective beta-1 blocker, it has less effect on peripheral beta-2 vasodilation (minimizing PAD symptom worsening) and less effect on airway beta-2 receptors (minimizing COPD worsening) than non-selective agents; the post-MI mortality benefit is a compelling indication that outweighs the relative contraindications of mild PAD and mild COPD; start at the lowest dose and monitor for claudication worsening and respiratory symptoms
B) Propranolol 40 mg twice daily is appropriate — its non-selective blockade provides superior anti-ischemic protection after MI compared to cardioselective agents because it also blocks beta-2-mediated vasodilation in coronary vessels, preventing vasospasm
C) All beta-blockers are absolutely contraindicated in this patient because the combination of PAD and COPD represents a dual contraindication that overrides any post-MI indication
D) Carvedilol is preferred over metoprolol in this patient because carvedilol's alpha-1 blockade will improve peripheral arterial blood flow and offset the peripheral vasoconstrictive effect of beta-2 blockade on PAD symptoms
E) Atenolol is the preferred post-MI beta-blocker in patients with PAD because its once-daily renal elimination profile produces more consistent plasma levels than hepatically-metabolized agents, reducing peak-concentration adverse effects on peripheral vessels
ANSWER: A
Rationale:
This patient has a compelling indication for beta-blocker therapy — post-MI mortality reduction — that must be weighed against relative contraindications (mild PAD, mild COPD). The evidence base clearly supports continuing beta-blockers in post-MI patients with mild-to-moderate COPD and mild PAD, where the absolute mortality benefit outweighs the manageable incremental adverse effects. Metoprolol succinate is the appropriate choice: it is one of the three evidence-based beta-blockers for HFrEF and has established post-MI benefit; its high cardioselectivity (beta-1 preferential) means less peripheral beta-2 blockade compared to non-selective agents — less vasoconstriction worsening PAD symptoms, and less bronchoconstriction affecting the airways. Starting at the lowest dose with monitoring for claudication worsening and respiratory symptoms is the correct approach.
Option B: Option B is incorrect because propranolol is non-selective and would worsen both PAD (beta-2 blockade removing vasodilatory tone) and COPD (airway beta-2 blockade causing bronchoconstriction); it has no outcome trial advantage over cardioselective agents in post-MI.
Option C: Option C is incorrect because mild PAD and mild COPD are relative contraindications, not absolute contraindications, when a post-MI compelling indication is present; guidelines support cardioselective beta-blocker use in this setting.
Option D: Option D is incorrect because while carvedilol's alpha-1 blockade does reduce peripheral resistance, the combined non-selective beta-blockade (including beta-2) in carvedilol can still worsen COPD symptoms and potentially affect PAD; metoprolol's higher beta-1 selectivity is preferable in this specific patient.
Option E: Option E is incorrect because atenolol's renal elimination profile is not the relevant criterion for post-MI agent selection; and atenolol lacks the robust HFrEF and post-MI outcome trial evidence that metoprolol succinate has.
9. A 67-year-old man with severe treatment-resistant hypertension (BP 194/108 mmHg on five agents) is started on minoxidil 5 mg daily in addition to his existing regimen of lisinopril 40 mg, amlodipine 10 mg, chlorthalidone 25 mg, and bisoprolol 10 mg daily. At his 6-week follow-up, BP is 152/88 mmHg — significantly improved but still above target. He has gained 4 kg and has bilateral ankle edema. His physician considers increasing the minoxidil dose. Which of the following most accurately identifies the pharmacological issue and the correct next step?
A) The weight gain and edema represent amlodipine-associated peripheral edema that has worsened because minoxidil's arteriolar dilation compounded the CCB-mediated capillary hydrostatic pressure increase; amlodipine should be discontinued before increasing minoxidil
B) The weight gain and edema indicate that minoxidil is not working — the fluid retention is a sign of inadequate blood pressure control that will resolve when the dose is increased
C) The weight gain and edema are caused by bisoprolol-mediated fluid retention — beta-blockers reduce renal perfusion pressure through cardiac output reduction, impairing natriuresis; bisoprolol should be discontinued and replaced with a loop diuretic
D) The weight gain and edema reflect inadequate diuretic therapy for the degree of sodium retention that minoxidil causes through secondary RAAS activation; chlorthalidone 25 mg is likely insufficient for minoxidil-associated fluid retention in a patient with this degree of hypertension — switching the diuretic to furosemide or torsemide (a loop diuretic) at an appropriate dose should be the first step before increasing minoxidil; if the loop diuretic resolves the edema and reveals residual hypertension, then minoxidil dose escalation is appropriate
E) The weight gain and edema are caused by lisinopril-mediated sodium retention from excessive RAAS suppression; the lisinopril dose should be reduced to allow physiological RAAS activity to maintain sodium balance
ANSWER: D
Rationale:
The 4 kg weight gain and bilateral ankle edema in a patient started on minoxidil represent inadequate diuretic therapy — the most common management error when initiating minoxidil. Minoxidil causes profound sodium and fluid retention through two mechanisms: reflex sympathetic activation stimulating renin release and secondary RAAS activation; and direct renal sodium retention through mechanisms independent of the RAAS. This fluid retention is frequently severe enough that thiazide-type diuretics (including chlorthalidone 25 mg) are inadequate — a loop diuretic is typically required. This is a fundamental principle of minoxidil prescribing. The correct next step is not to increase the minoxidil dose in the setting of uncontrolled fluid retention — the edema must be addressed first by switching to or adding a loop diuretic. If adequate diuresis then reveals residual hypertension despite good volume control, minoxidil dose escalation is appropriate at that point. The bisoprolol in this regimen is correctly co-prescribed to prevent reflex tachycardia — it should not be discontinued.
Option A: Option A is incorrect because the primary mechanism of the edema is sodium retention from minoxidil's secondary RAAS effects, not amlodipine-mediated capillary hydrostatic pressure; amlodipine should not be discontinued.
Option B: Option B is incorrect because the fluid retention is a pharmacological consequence of minoxidil's mechanism, not evidence of therapeutic failure; increasing the dose without addressing the diuretic inadequacy would worsen fluid retention.
Option C: Option C is incorrect because bisoprolol does not cause fluid retention through renal perfusion reduction; this mechanism is not established at therapeutic beta-blocker doses.
Option E: Option E is incorrect because lisinopril does not cause sodium retention — RAAS inhibition reduces, not increases, sodium retention; the fluid retention is from minoxidil.
10. A 52-year-old man with hypertension and newly diagnosed type 2 diabetes is on metoprolol succinate 100 mg daily (started two years ago for hypertension) and his HbA1c is 7.9%. His diabetologist notes that his HbA1c is higher than expected given his dietary compliance and attributes part of the difficulty to his beta-blocker. Which of the following most accurately describes the pharmacological basis for this concern and the appropriate clinical response?
A) Metoprolol succinate should be immediately discontinued — beta-blockers are absolutely contraindicated in type 2 diabetes because they cause irreversible impairment of insulin receptor signaling through beta-1 receptor-mediated inhibition of the insulin signaling cascade
B) Metoprolol succinate worsens glycemic control in type 2 diabetes through several mechanisms: beta-1 blockade reduces insulin secretion from pancreatic beta cells (which are partially regulated by sympathetic beta-1 stimulation); beta-2 blockade (even partial, given the relative selectivity) impairs glucose uptake in skeletal muscle and impairs glycogenolysis needed for glucose counter-regulation; and beta-blockers reduce the adrenergic warning symptoms that help patients identify and respond to hypoglycemia early; however, if metoprolol was initiated for a compelling indication (which in this case is hypertension only — not post-MI or HFrEF), reassessing whether a non-beta-blocker antihypertensive would achieve equivalent BP control while improving glycemic management is reasonable
C) The elevated HbA1c is unrelated to metoprolol — cardioselective beta-blockers have no effect on glucose metabolism or insulin sensitivity in type 2 diabetes; the diabetologist's attribution is incorrect
D) Metoprolol must be replaced with carvedilol — carvedilol improves insulin sensitivity through its alpha-1 blockade, which reduces hepatic glucose output, making it the preferred beta-blocker in all diabetic patients with hypertension
E) The glycemic effects of metoprolol are entirely mediated through beta-2 receptors; switching to a more cardioselective agent such as bisoprolol will completely eliminate the glycemic adverse effects while maintaining antihypertensive efficacy
ANSWER: B
Rationale:
Beta-blockers, including cardioselective agents, have a complex and clinically meaningful interaction with glucose metabolism in type 2 diabetes. Beta-1 stimulation of pancreatic islet cells contributes to insulin secretion — beta-1 blockade modestly reduces this sympathetically-driven insulin release. Residual beta-2 blockade (even with cardioselective agents) in skeletal muscle impairs glucose uptake and glycogenolysis, contributing to impaired glucose counter-regulation. Additionally, beta-blockers mask the adrenergic warning symptoms of hypoglycemia (palpitations, tremor, tachycardia) — this is particularly relevant when hypoglycemia-inducing agents are used. These combined effects can worsen HbA1c by approximately 0.5–1% in some patients on beta-blockers. The appropriate clinical response depends on the indication: if metoprolol was started for a compelling indication with proven mortality benefit (post-MI, HFrEF), the glycemic impact must be accepted or managed with adjustments in diabetes therapy. If — as in this case — metoprolol is used only for hypertension without a compelling beta-blocker indication, reassessing the regimen and potentially switching to a drug class with a more favorable metabolic profile (CCB, ACEi, ARB) is a reasonable clinical decision.
Option A: Option A is incorrect because beta-blockers are not absolutely contraindicated in type 2 diabetes; they are used cautiously when indicated, particularly post-MI or in HFrEF.
Option C: Option C is incorrect because cardioselective beta-blockers do have measurable effects on glucose metabolism; the effects are lesser than non-selective agents but not absent.
Option D: Option D is incorrect because carvedilol does not improve insulin sensitivity through reduction of hepatic glucose output via alpha-1 blockade; this mechanism is not established.
Option E: Option E is incorrect because the glycemic effects are not entirely beta-2 mediated; beta-1 effects on pancreatic insulin secretion contribute, and switching to bisoprolol would reduce but not completely eliminate metabolic concerns.
11. A 70-year-old woman with hypertension, HFrEF (EF 28%), and atrial fibrillation is admitted with acute decompensated heart failure. Her BP on admission is 176/104 mmHg and heart rate is 118 bpm. She is volume overloaded with 3+ bilateral pitting edema and orthopnea. Her home medications include carvedilol 25 mg twice daily, sacubitril/valsartan 97/103 mg twice daily, and spironolactone 25 mg daily. Which of the following most accurately describes the appropriate management of her carvedilol during the acute admission?
A) Increase carvedilol to the maximum dose of 50 mg twice daily — the elevated heart rate indicates inadequate beta-blockade, and increasing the dose will provide better rate control and reduce myocardial oxygen demand during the decompensation
B) Discontinue carvedilol immediately and permanently — beta-blockers are contraindicated in decompensated HFrEF and should not be restarted once the patient has been decompensated
C) Reduce or temporarily hold carvedilol — initiating or maintaining full-dose beta-blockade during acute decompensated HFrEF risks further reducing cardiac output in a state where the decompensated heart is already dependent on compensatory sympathetic activation to maintain perfusion; the standard approach is to reduce the dose (not abruptly stop) or temporarily hold during the acute phase while aggressively managing volume overload with IV diuretics; once the patient is stabilized and euvolemic, carvedilol should be restarted and titrated back to the target dose
D) Continue carvedilol at the current dose unchanged — the tachycardia and hypertension indicate that the adrenergic drive is the primary pathophysiological mechanism and maximum beta-blockade should be maintained throughout the decompensation
E) Replace carvedilol with IV metoprolol tartrate — IV formulations provide better bioavailability than oral carvedilol during acute decompensation and metoprolol's beta-1 selectivity is superior to carvedilol's non-selective blockade in the acute setting
ANSWER: C
Rationale:
The management of beta-blockers during acute decompensated HFrEF is one of the most clinically important and frequently tested pharmacological decisions in cardiology. The principle is nuanced: beta-blockers should not be abruptly stopped (which risks rebound adrenergic activation and sudden worsening), but they should not be maintained at full dose when the patient is acutely decompensated. During acute decompensation, the failing heart is dependent on elevated sympathetic tone — through beta-1 receptor stimulation of the sinoatrial node and myocardium — to maintain cardiac output. Maintaining or increasing full-dose beta-blockade in this state risks further reducing an already critically compromised cardiac output, potentially causing cardiogenic shock. The standard approach is to reduce the carvedilol dose (by 50% or more, depending on hemodynamic status) or temporarily hold it during the acute phase while IV diuretics aggressively treat the volume overload. Once the patient achieves hemodynamic stability and euvolemia — typically over several days — carvedilol is restarted at a reduced dose and carefully re-titrated to the target.
Option A: Option A is incorrect because increasing beta-blocker dose during acute decompensation risks acute hemodynamic deterioration.
Option B: Option B is incorrect because abrupt discontinuation risks rebound adrenergic activation; and once stabilized, the patient absolutely should be restarted on carvedilol given its HFrEF mortality benefit.
Option D: Option D is incorrect because maintaining full-dose beta-blockade through decompensation without dose adjustment risks progressive hemodynamic compromise.
Option E: Option E is incorrect because switching to IV metoprolol is not indicated; the preferred approach is dose reduction of the existing oral agent, not route or agent substitution.
12. A 48-year-old man with hypertension on clonidine 0.2 mg twice daily is admitted for elective cholecystectomy. In the preoperative assessment, the anesthesiologist notes that clonidine has not been listed on the admission medication reconciliation form and was not given on the morning of surgery. The patient is now 14 hours post-last-dose in the preoperative holding area. His BP is 186/108 mmHg and heart rate is 96 bpm. He is diaphoretic and anxious. Which of the following most accurately identifies the diagnosis and the appropriate immediate management?
A) This is a hypertensive urgency from undertreated essential hypertension; IV hydralazine should be administered to acutely lower the blood pressure before proceeding with surgery
B) This is an anxiety-related blood pressure elevation from surgical anticipation; the surgery should proceed and the blood pressure will normalize once the patient receives general anesthesia
C) This is clonidine withdrawal syndrome; the surgery should be postponed and oral clonidine 0.2 mg should be given immediately; if the patient cannot take oral medications, a clonidine transdermal patch should be applied and IV labetalol given for acute BP control while waiting for oral therapy to take effect; the anesthesiology and surgical teams should be notified
D) This is clonidine withdrawal syndrome presenting as a hypertensive emergency; sodium nitroprusside infusion should be started immediately to achieve rapid blood pressure normalization before proceeding with surgery
E) This is clonidine withdrawal syndrome — abrupt cessation has removed central alpha-2-mediated sympathetic suppression; the upregulated peripheral sympathetic system is firing excessively, producing hypertension, tachycardia, diaphoresis, and anxiety; immediate management is oral clonidine 0.2 mg if the patient can swallow (with NPO status reassessed given the urgency), or IV labetalol for acute BP control while the anesthesiology team arranges a clonidine patch (understanding its 48-hour onset) or IV dexmedetomidine (a central alpha-2 agonist) as a bridge; the elective surgery should be postponed until hemodynamic stability is restored; medication reconciliation failure is the root cause and should be documented
ANSWER: E
Rationale:
This is a classic and preventable presentation of clonidine withdrawal syndrome precipitated by medication reconciliation failure on hospital admission. The timeline (14 hours post-last-dose) and clinical features (severe hypertension, tachycardia, diaphoresis, anxiety) are characteristic: after chronic clonidine therapy, peripheral adrenoceptors are upregulated in response to suppressed central sympathetic output; abrupt removal of the central alpha-2 stimulation causes unrestrained sympathetic firing from these sensitized receptors, producing a catecholamine-excess state clinically resembling pheochromocytoma. Management is multi-pronged: if the patient can swallow despite NPO status (NPO restrictions can often be modified for medications), oral clonidine 0.2 mg should be given immediately. IV labetalol provides acute blood pressure control through combined alpha-1 and beta-1 blockade while oral clonidine is loading. A clonidine transdermal patch (noting its 48-hour onset — not useful for acute control but provides sustained delivery once established). IV dexmedetomidine (a highly selective alpha-2 agonist used in ICU sedation) can serve as a bridge in patients unable to take oral medications. The elective surgery must be postponed — proceeding in a hemodynamically unstable patient with active withdrawal syndrome creates unacceptable anesthetic risk. Option C is largely correct but omits the 48-hour onset limitation of the transdermal patch and the role of dexmedetomidine as a bridge, making E more complete.
Option A: Option A is incorrect because this is not simple untreated hypertension; treating it with hydralazine without recognizing the withdrawal syndrome fails to address the mechanism.
Option B: Option B is incorrect because BP of 186/108 mmHg with diaphoresis and tachycardia is not anxiety alone and cannot be attributed to surgical anticipation.
Option D: Option D is incorrect because sodium nitroprusside is an aggressive choice for this scenario; it does not address the underlying withdrawal mechanism and creates risks of excessive BP reduction.
13. A 63-year-old man with hypertension, HFrEF (EF 34%), and type 2 diabetes presents for routine follow-up. He is on carvedilol 25 mg twice daily, sacubitril/valsartan 97/103 mg twice daily, and empagliflozin 10 mg daily. His BP is 148/84 mmHg and heart rate is 62 bpm. His physician considers adding a fourth agent for additional BP control. She considers doxazosin 1 mg daily. Which of the following most accurately evaluates this choice in the context of his complete clinical profile?
A) Doxazosin is a poor choice in this patient for several pharmacologically grounded reasons: first, ALLHAT demonstrated that doxazosin produces inferior cardiovascular protection compared to thiazide diuretics, with higher heart failure rates — particularly concerning in a patient with established HFrEF; second, carvedilol's alpha-1 blockade is already present in his regimen, making doxazosin's mechanism partially redundant; third, doxazosin's first-dose orthostatic hypotension risk is compounded by sacubitril/valsartan's vasodilatory effects and empagliflozin's volume-depleting osmotic diuresis, creating significant fall risk in a patient whose heart rate is already 62 bpm; a mechanistically cleaner addition would be amlodipine (CCB — no ALLHAT concerns, no redundant mechanism, no orthostatic risk, hemodynamically neutral in HFrEF per V-HeFT III)
B) Doxazosin is the ideal fourth agent because its alpha-1 blockade is complementary to carvedilol's beta-blockade, and the two agents together achieve complete adrenergic receptor blockade
C) Doxazosin is appropriate — the ALLHAT concern applies only to Black patients in whom thiazides have stronger evidence; in non-Black patients doxazosin is equivalent to other antihypertensives for cardiovascular protection
D) Doxazosin should be avoided only because of its first-dose orthostatic hypotension risk; if started at 0.5 mg and titrated slowly, the ALLHAT cardiovascular concerns do not apply at low doses
E) Doxazosin is the preferred agent because alpha-1 blockade specifically reduces the increased peripheral vascular resistance that is the dominant hemodynamic abnormality in HFrEF, directly targeting the afterload excess that impairs stroke volume
ANSWER: A
Rationale:
Doxazosin is a poor pharmacological choice for this specific patient for multiple overlapping reasons. First, the ALLHAT finding of excess heart failure with doxazosin is particularly concerning in a patient who already has HFrEF — the cardiovascular protection argument against alpha-1 blockers applies with even greater force when the patient has established left ventricular dysfunction. Second, carvedilol already provides alpha-1 blockade as part of its combined receptor pharmacology — adding doxazosin creates redundant alpha-1 blockade with no additional therapeutic benefit. Third, the orthostatic hypotension risk from doxazosin is compounded by the vasodilatory effects of sacubitril/valsartan (which reduces angiotensin II-mediated vasoconstriction and aldosterone-driven sodium retention) and empagliflozin's osmotic diuresis (which produces modest volume depletion). His heart rate of 62 bpm means he has limited chronotropic reserve to compensate for orthostatic hypotension, increasing fall risk. Amlodipine is the mechanistically correct addition: it provides antihypertensive benefit through vascular L-type calcium channel blockade (a mechanism not present in the current regimen), is hemodynamically neutral in HFrEF (V-HeFT III), has no interaction with his existing agents, and carries no orthostatic hypotension risk.
Option B: Option B is incorrect because "complete adrenergic blockade" is not a therapeutic goal; the redundant mechanism adds risk without benefit.
Option C: Option C is incorrect because ALLHAT's doxazosin findings applied to the entire enrolled population, not only Black patients.
Option D: Option D is incorrect because the ALLHAT cardiovascular risk signal was not dose-dependent in the trial data; it reflects the fundamental pharmacological difference between alpha-1 blockers and thiazide diuretics in cardiovascular protection.
Option E: Option E is incorrect because while afterload reduction is a hemodynamic goal in HFrEF, doxazosin's specific risks in this patient outweigh the hemodynamic rationale; amlodipine provides afterload reduction without the safety concerns.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.